Acute Promyelocytic Leukemia Clinical Trials

42 clinical trials for Acute Promyelocytic Leukemia across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia — RECRUITING · PHASE3
• A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia — RECRUITING · PHASE3
• Frontline Oral Arsenic Trioxide for APL — RECRUITING · PHASE2
• Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia — RECRUITING · PHASE2
• Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients — RECRUITING · PHASE2
• Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia — RECRUITING · PHASE2
• Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients — NOT_YET_RECRUITING · PHASE2
• Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia — COMPLETED · PHASE3
• A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) — NOT_YET_RECRUITING · PHASE3
• French Registry of First-line Treatment of Acute Promyelocytic Leukemia — ACTIVE_NOT_RECRUITING
• Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia — COMPLETED · PHASE1
• AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment — COMPLETED · NA
• Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia — ACTIVE_NOT_RECRUITING · NA
• Optimum Induction Therapy of Low-risk APL — OTHER · NA
• A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia — SUSPENDED · PHASE1
• Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia — ACTIVE_NOT_RECRUITING
• Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy — COMPLETED
• Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia — OTHER · PHASE2
• The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project — OTHER
• Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia — OTHER
• Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy — COMPLETED · PHASE2
• Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) — OTHER · PHASE3
• Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy — OTHER
• AIDA 2000 Guidelines — OTHER · PHASE2
• Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL — OTHER · PHASE4
• All-trans Retinoic Acid, and Arsenic +/- Idarubicin — COMPLETED · PHASE2
• Red Cell Transfusion Goals in Patients With Acute Leukemias — COMPLETED · PHASE1
• Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia — OTHER
• Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias — TERMINATED · PHASE1
• A Safety Study of SGN-CD33A in AML Patients — COMPLETED · PHASE1
• Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia — OTHER · PHASE3
• New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia — WITHDRAWN · PHASE2
• ASCT for Relapsed APL After Molecular Remission — TERMINATED · PHASE2
• Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) — COMPLETED · PHASE4
• Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) — COMPLETED · PHASE4
• Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia — COMPLETED
• Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia — TERMINATED · PHASE1
• Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler — TERMINATED
• Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL — COMPLETED · PHASE2
• Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia — OTHER · PHASE2
• Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) — COMPLETED · PHASE4
• Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia — OTHER · PHASE2

Refine this search